Effect of major ABO blood group mismatched HSCT on blood transfusion and clinical outcomes in AA patients
- PMID: 40102306
- PMCID: PMC12031907
- DOI: 10.1007/s00277-025-06213-4
Effect of major ABO blood group mismatched HSCT on blood transfusion and clinical outcomes in AA patients
Abstract
To investigate the impact of the ABO blood group major match type on stem cell engraftment, blood transfusion and clinical outcomes in aplastic anemia patients with hematopoietic stem cell transplantation (HSCT), we retrospectively analyzed the data of 361 aplastic anemia patients treated with HSCT, and found ABO major mismatched resulted in delayed red blood cells (RBCs) engraftment and ABO blood group conversion. The patients in the ABO major mismatched group required more units of RBCs and PLTs transfusions. Multivariate linear regression analysis showed that ABO mismatched, acute graft-versus-host disease (aGVHD), time to RBCs and PLTs engraftment and blood group conversion, and baseline hemoglobin were significantly associated with RBCs transfusion, the factors associated with PLTs transfusion were the PLTs, RBCs and neutrophils engraftment, graft rejection, baseline PLTs, aGVHD grade II-IV, and severe chronic GVHD. Multivariate analysis showed that the time to neutrophils engraftment, baseline hemoglobin, and aGVHD were independent poor prognostic factors to both overall survival and failure-free survival. Moreover, the major ABO-mismatched HSCT group were hospitalized more often. These findings suggest that it's better to select a donor with an ABO major match to reduce the burden of transfusion and the impact of hospitalization, if conditions permit.
Keywords: ABO blood group; Aplastic anemia; Hematopoietic stem cell transplantation; Major mismatched transplantation; Survival analysis; Transfusion.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Figures




Similar articles
-
The impact of ABO compatibility/incompatibility between donor and recipient of allogeneic bone marrow transplant on transplant outcomes.Transpl Immunol. 2025 Jun;91:102231. doi: 10.1016/j.trim.2025.102231. Epub 2025 May 8. Transpl Immunol. 2025. PMID: 40345257
-
Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source.Biol Blood Marrow Transplant. 2010 Sep;16(9):1315-23. doi: 10.1016/j.bbmt.2010.03.021. Epub 2010 Mar 29. Biol Blood Marrow Transplant. 2010. PMID: 20353831
-
Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation.Transfus Clin Biol. 2020 Aug;27(3):115-121. doi: 10.1016/j.tracli.2020.06.008. Epub 2020 Jul 10. Transfus Clin Biol. 2020. PMID: 32659269
-
ABO blood group mismatched hematopoietic stem cell transplantation.Transfus Apher Sci. 2016 Feb;54(1):24-9. doi: 10.1016/j.transci.2016.01.008. Epub 2016 Jan 11. Transfus Apher Sci. 2016. PMID: 26810142 Review.
-
Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.Transfusion. 2005 Oct;45(10):1676-83. doi: 10.1111/j.1537-2995.2005.00578.x. Transfusion. 2005. PMID: 16181220 Review.
References
-
- Bacigalupo A (2017) How I treat acquired aplastic anemia. Blood 129(11):1428–1436. 10.1182/blood-2016-08-693481 - PubMed
-
- Lv M, Chang Y, Huang X (2019) Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation. Frontiers of medicine 13(1):45–56. 10.1007/s11684-017-0595-7 - PubMed
-
- Zhang Y, Huo J, Liu L, Shen Y, Chen J, Zhang T, Chen X, Pang A, Yang D, Zhang R, Ma Q, Zhai W, He Y, Wei J, Jiang E, Han M, Zheng Y, Feng S (2022) Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia. Front Immunol 13:837335 - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical